Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Theravance Biopharma (TBPH) has disclosed Convertible Debt for 7 consecutive years, with $228.6 million as the latest value for Q2 2022.

  • Quarterly Convertible Debt changed 0.47% to $228.6 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $228.6 million through Jun 2022, changed 0.47% year-over-year, with the annual reading at $228.0 million for FY2021, 0.47% changed from the prior year.
  • Convertible Debt for Q2 2022 was $228.6 million at Theravance Biopharma, roughly flat from $228.3 million in the prior quarter.
  • The five-year high for Convertible Debt was $228.6 million in Q2 2022, with the low at $224.0 million in Q1 2018.
  • Average Convertible Debt over 5 years is $226.3 million, with a median of $226.3 million recorded in 2020.
  • The sharpest move saw Convertible Debt increased 0.48% in 2018, then grew 0.47% in 2022.
  • Over 5 years, Convertible Debt stood at $224.8 million in 2018, then increased by 0.48% to $225.9 million in 2019, then increased by 0.48% to $227.0 million in 2020, then grew by 0.47% to $228.0 million in 2021, then grew by 0.24% to $228.6 million in 2022.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $228.6 million, $228.3 million, and $228.0 million for Q2 2022, Q1 2022, and Q4 2021 respectively.